Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas

Jian L. Campian, Xiaobu Ye, Douglas E. Gladstone, Prakash Ambady, Thomas R. Nirschl, Ivan Borrello, Marc Golightly, Karen E. King, Matthias Holdhoff, Judith Karp, Charles G. Drake, Stuart A. Grossman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Radiation (RT), temozolomide (TMZ), and dexamethasone in newly diagnosed high grade gliomas (HGG) produces severe treatment-related lymphopenia (TRL) that is associated with early cancer-related deaths. This TRL may result from inadvertent radiation to circulating lymphocytes. This study reinfused lymphocytes, harvested before chemo-radiation, and assessed safety, feasibility, and trends in lymphocyte counts. Patients with newly diagnosed HGG and total lymphocyte counts (TLC) ≥ 1000 cells/mm3 underwent apheresis. Cryopreserved autologous lymphocytes were reinfused once radiation was completed. Safety, feasibility, and trends in TLC, T cell subsets and cytokines were studied. Serial TLC were also compared with an unreinfused matched control group. Ten patients were harvested (median values: age 56 years, dexamethasone 3 mg/day, TLC/CD4 1980/772 cells/mm3). After 6 weeks of RT/TMZ, TLC fell 69 % (p 7 lymphocytes/kg) without adverse events. A post-reinfusion TLC rise of ≥300 cells/mm3 was noted in 3/8 patients at 4 weeks and 7/8 at 14 weeks which was similar to 23 matched controls. The reduced CD4/CD8 ratio was not restored by lymphocyte reinfusion. Severe lymphopenia was not accompanied by elevated serum interleukin-7 (IL-7) levels. This study confirms that severe TRL is common in HGG and is not associated with high plasma IL-7 levels. Although lymphocyte harvesting/reinfusion is feasible and safe, serial lymphocyte counts are similar to unreinfused matched controls. Studies administering higher lymphocyte doses and/or IL-7 should be considered to restore severe treatment-related lymphopenia in HGG.

Original languageEnglish (US)
Pages (from-to)307-316
Number of pages10
JournalJournal of Neuro-Oncology
Volume124
Issue number2
DOIs
StatePublished - Jun 13 2015

Fingerprint

Lymphocyte Count
Glioma
Lymphopenia
Lymphocytes
Radiation
temozolomide
Interleukin-7
Dexamethasone
Safety
CD4-CD8 Ratio
Blood Component Removal
T-Lymphocyte Subsets
Therapeutics
Research Design
Cytokines
Control Groups
Serum

Keywords

  • High grade glioma
  • IL-7
  • Lymphocyte reinfusion
  • Lymphopenia
  • Radiation

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. / Campian, Jian L.; Ye, Xiaobu; Gladstone, Douglas E.; Ambady, Prakash; Nirschl, Thomas R.; Borrello, Ivan; Golightly, Marc; King, Karen E.; Holdhoff, Matthias; Karp, Judith; Drake, Charles G.; Grossman, Stuart A.

In: Journal of Neuro-Oncology, Vol. 124, No. 2, 13.06.2015, p. 307-316.

Research output: Contribution to journalArticle

Campian, JL, Ye, X, Gladstone, DE, Ambady, P, Nirschl, TR, Borrello, I, Golightly, M, King, KE, Holdhoff, M, Karp, J, Drake, CG & Grossman, SA 2015, 'Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas', Journal of Neuro-Oncology, vol. 124, no. 2, pp. 307-316. https://doi.org/10.1007/s11060-015-1841-y
Campian, Jian L. ; Ye, Xiaobu ; Gladstone, Douglas E. ; Ambady, Prakash ; Nirschl, Thomas R. ; Borrello, Ivan ; Golightly, Marc ; King, Karen E. ; Holdhoff, Matthias ; Karp, Judith ; Drake, Charles G. ; Grossman, Stuart A. / Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. In: Journal of Neuro-Oncology. 2015 ; Vol. 124, No. 2. pp. 307-316.
@article{d59d25020999460e936ec961cfc0bbaf,
title = "Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas",
abstract = "Radiation (RT), temozolomide (TMZ), and dexamethasone in newly diagnosed high grade gliomas (HGG) produces severe treatment-related lymphopenia (TRL) that is associated with early cancer-related deaths. This TRL may result from inadvertent radiation to circulating lymphocytes. This study reinfused lymphocytes, harvested before chemo-radiation, and assessed safety, feasibility, and trends in lymphocyte counts. Patients with newly diagnosed HGG and total lymphocyte counts (TLC) ≥ 1000 cells/mm3 underwent apheresis. Cryopreserved autologous lymphocytes were reinfused once radiation was completed. Safety, feasibility, and trends in TLC, T cell subsets and cytokines were studied. Serial TLC were also compared with an unreinfused matched control group. Ten patients were harvested (median values: age 56 years, dexamethasone 3 mg/day, TLC/CD4 1980/772 cells/mm3). After 6 weeks of RT/TMZ, TLC fell 69 {\%} (p 7 lymphocytes/kg) without adverse events. A post-reinfusion TLC rise of ≥300 cells/mm3 was noted in 3/8 patients at 4 weeks and 7/8 at 14 weeks which was similar to 23 matched controls. The reduced CD4/CD8 ratio was not restored by lymphocyte reinfusion. Severe lymphopenia was not accompanied by elevated serum interleukin-7 (IL-7) levels. This study confirms that severe TRL is common in HGG and is not associated with high plasma IL-7 levels. Although lymphocyte harvesting/reinfusion is feasible and safe, serial lymphocyte counts are similar to unreinfused matched controls. Studies administering higher lymphocyte doses and/or IL-7 should be considered to restore severe treatment-related lymphopenia in HGG.",
keywords = "High grade glioma, IL-7, Lymphocyte reinfusion, Lymphopenia, Radiation",
author = "Campian, {Jian L.} and Xiaobu Ye and Gladstone, {Douglas E.} and Prakash Ambady and Nirschl, {Thomas R.} and Ivan Borrello and Marc Golightly and King, {Karen E.} and Matthias Holdhoff and Judith Karp and Drake, {Charles G.} and Grossman, {Stuart A.}",
year = "2015",
month = "6",
day = "13",
doi = "10.1007/s11060-015-1841-y",
language = "English (US)",
volume = "124",
pages = "307--316",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas

AU - Campian, Jian L.

AU - Ye, Xiaobu

AU - Gladstone, Douglas E.

AU - Ambady, Prakash

AU - Nirschl, Thomas R.

AU - Borrello, Ivan

AU - Golightly, Marc

AU - King, Karen E.

AU - Holdhoff, Matthias

AU - Karp, Judith

AU - Drake, Charles G.

AU - Grossman, Stuart A.

PY - 2015/6/13

Y1 - 2015/6/13

N2 - Radiation (RT), temozolomide (TMZ), and dexamethasone in newly diagnosed high grade gliomas (HGG) produces severe treatment-related lymphopenia (TRL) that is associated with early cancer-related deaths. This TRL may result from inadvertent radiation to circulating lymphocytes. This study reinfused lymphocytes, harvested before chemo-radiation, and assessed safety, feasibility, and trends in lymphocyte counts. Patients with newly diagnosed HGG and total lymphocyte counts (TLC) ≥ 1000 cells/mm3 underwent apheresis. Cryopreserved autologous lymphocytes were reinfused once radiation was completed. Safety, feasibility, and trends in TLC, T cell subsets and cytokines were studied. Serial TLC were also compared with an unreinfused matched control group. Ten patients were harvested (median values: age 56 years, dexamethasone 3 mg/day, TLC/CD4 1980/772 cells/mm3). After 6 weeks of RT/TMZ, TLC fell 69 % (p 7 lymphocytes/kg) without adverse events. A post-reinfusion TLC rise of ≥300 cells/mm3 was noted in 3/8 patients at 4 weeks and 7/8 at 14 weeks which was similar to 23 matched controls. The reduced CD4/CD8 ratio was not restored by lymphocyte reinfusion. Severe lymphopenia was not accompanied by elevated serum interleukin-7 (IL-7) levels. This study confirms that severe TRL is common in HGG and is not associated with high plasma IL-7 levels. Although lymphocyte harvesting/reinfusion is feasible and safe, serial lymphocyte counts are similar to unreinfused matched controls. Studies administering higher lymphocyte doses and/or IL-7 should be considered to restore severe treatment-related lymphopenia in HGG.

AB - Radiation (RT), temozolomide (TMZ), and dexamethasone in newly diagnosed high grade gliomas (HGG) produces severe treatment-related lymphopenia (TRL) that is associated with early cancer-related deaths. This TRL may result from inadvertent radiation to circulating lymphocytes. This study reinfused lymphocytes, harvested before chemo-radiation, and assessed safety, feasibility, and trends in lymphocyte counts. Patients with newly diagnosed HGG and total lymphocyte counts (TLC) ≥ 1000 cells/mm3 underwent apheresis. Cryopreserved autologous lymphocytes were reinfused once radiation was completed. Safety, feasibility, and trends in TLC, T cell subsets and cytokines were studied. Serial TLC were also compared with an unreinfused matched control group. Ten patients were harvested (median values: age 56 years, dexamethasone 3 mg/day, TLC/CD4 1980/772 cells/mm3). After 6 weeks of RT/TMZ, TLC fell 69 % (p 7 lymphocytes/kg) without adverse events. A post-reinfusion TLC rise of ≥300 cells/mm3 was noted in 3/8 patients at 4 weeks and 7/8 at 14 weeks which was similar to 23 matched controls. The reduced CD4/CD8 ratio was not restored by lymphocyte reinfusion. Severe lymphopenia was not accompanied by elevated serum interleukin-7 (IL-7) levels. This study confirms that severe TRL is common in HGG and is not associated with high plasma IL-7 levels. Although lymphocyte harvesting/reinfusion is feasible and safe, serial lymphocyte counts are similar to unreinfused matched controls. Studies administering higher lymphocyte doses and/or IL-7 should be considered to restore severe treatment-related lymphopenia in HGG.

KW - High grade glioma

KW - IL-7

KW - Lymphocyte reinfusion

KW - Lymphopenia

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84942501867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942501867&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1841-y

DO - 10.1007/s11060-015-1841-y

M3 - Article

VL - 124

SP - 307

EP - 316

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -